Invention Grant
![Substituted imidazo[1,5-a]pyrazines as Btk inhibitors](/docs/US/2018-08-07/US10040805B2/abs.jpg.600x600.jpg)
- Patent Title: Substituted imidazo[1,5-a]pyrazines as Btk inhibitors
-
Application No.: US15538957Application Date: 2015-12-17
-
Publication No.: US10040805B2Publication Date: 2018-08-07
- Inventor: Jian Liu , Joseph A. Kozlowski , Xiaolei Gao , Deodial Guy Guiadeen , Shilan Liu , Dahai Wang
- Applicant: MERCK SHARP & DOHME CORP.
- Applicant Address: US NJ Rahway
- Assignee: Merck Sharp & Dohme Corp.
- Current Assignee: Merck Sharp & Dohme Corp.
- Current Assignee Address: US NJ Rahway
- Agent Matthew A. Leff; Laura Ginkel
- Priority: WOPCT/CN2014/095767 20141231
- International Application: PCT/US2015/066225 WO 20151217
- International Announcement: WO2016/109220 WO 20160707
- Main IPC: A61K31/4985
- IPC: A61K31/4985 ; C07D487/04 ; C07D519/00
![Substituted imidazo[1,5-a]pyrazines as Btk inhibitors](/abs-image/US/2018/08/07/US10040805B2/abs.jpg.150x150.jpg)
Abstract:
The present invention provides Bruton's Tyrosine Kinase (Btk) inhibitor compounds according to Formula (I), or pharmaceutically acceptable salts thereof, Formula (I) or to pharmaceutical compositions comprising these compounds and to their use in therapy. In particular, the present invention relates to the use of Btk inhibitor compounds of Formula I in the treatment of Btk mediated disorders.
Public/Granted literature
- US20180009828A1 IMIDAZOPYRAZINE ANALOGS WITH 3-TERTIARY CARBON SUBSTITUTIONS AS BTK INHIBITORS Public/Granted day:2018-01-11
Information query
IPC分类:
